DNLI - CIK 0001714899
Denali Therapeutics Inc. (DNLI) reported net income of -$512.54M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$512.54M | -21.2% |
| FY 2024 | -$422.77M | -191.1% |
| FY 2023 | -$145.22M | +55.5% |
| FY 2022 | -$325.99M | -12.2% |
| FY 2021 | -$290.58M | -508.5% |
| FY 2020 | $71.14M | +136.0% |
| FY 2019 | -$197.61M | -445.3% |
| FY 2018 | -$36.24M | +58.9% |
| FY 2017 |
Denali Therapeutics Inc. (DNLI) reported net income of -$512.54M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Denali Therapeutics Inc.'s net income declined from -$86.65M to -$512.54M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$88.19M |
| -1.8% |
| FY 2016 | -$86.65M | - |